Carmell Therapeutics - רווח החברה לפני מסים, ריבית ופחת XAGE

Longevity Health Holdings (XAGE) price action is driven by the development of regenerative aesthetics and plasma technologies within the Carmel line. The EBITDA figures visualize this process, where the level records fresh values. Growth is based on the sale of bioactive skin rejuvenation cosmetics, while stability is maintained through strict adherence to sanitary standards and environmental waste disposal controls.

The commercialization of regenerative products and the expansion of e-commerce distribution at Longevity Health Holdings (XAGE) directly determine the EBITDA_Co level on this chart. This metric measures net cash flow from operating activities before depreciation and taxes, allowing investors to assess the core business's actual ability to act as a cash generator and the efficiency of cost management relative to the company's market value.